# Codex Review: medical_monitoring_release_gate_strict_shapes_20260804

Date: 2026-08-04
Delegated-agent output: none; direct Codex task

## Verdict

**Pass for the pure commercial release-gate input-shape contract only.** The
change prevents malformed IDs, hashes, summaries, B6 status and decision flags
from being silently normalized, while preserving the existing blocked release
decision and authority boundary.

## Boundary Check

- Codex must confirm the delegated agent stayed inside allowed paths.
- Codex must confirm only the requested output file was written.

No delegated agent was used; the Hermes workflow guard was used for task and
review-gate bookkeeping. Direct changes are limited to the release-gate
module, its focused tests, the current release snapshot's two source hash
declarations, and this task's evidence/review/metrics/context files. No
runtime, database, source data, B6/C14, medical-writing or listener state was
modified.

## Codex Verification

- Focused release-gate suite: **10 passed**.
- Adjacent release evidence/dossier/nonfunctional revalidation suites: **35
  passed**.
- `py_compile` for changed Python source/tests: passed.
- Current release snapshot revalidation remains fresh; the release decision is
  still `blocked`, `release_ready=false`, B6 `pending_review` and all authority
  flags false.
- Ruff was not available on PATH, so no Ruff result is asserted.
- Browser/PPT/PDF/live authority checks were intentionally not run because the
  current B6/C14/real-loop gate forbids runtime activation.

## Delegated-Agent Output Review

Not applicable. Direct Codex review traced the implementation to the release
gate source, focused tests, persisted coverage snapshot and current real-loop
gate audit. The snapshot hash declarations were refreshed because the source
and test files changed; no gate status was promoted.

## Residual Risk

The strict-shape guard does not prove B6 medical outcomes, source-token
lineage, aggregate/CAS replay, continuous real-project batches,
independent-product-AI generalization, scientific/UI acceptance, or commercial
release. The next safe action remains formal reviewer outcomes, then approved
source-token and aggregate/CAS revalidation; keep 8911/5174/8910/4173 stopped.
